Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2C | P28335 | 6/20 | 0.58 |
| ▸ | HTR2A | P28223 | 2/20 | 0.44 |
| ▸ | HTR6 | P50406 | 5/20 | 0.43 |
| ▸ | SLC6A2 | P23975 | 6/20 | 0.43 |
| ▸ | SLC6A4 | P31645 | 6/20 | 0.43 |
| ▸ | SLC6A3 | Q01959 | 6/20 | 0.43 |
| ▸ | HTR1A | P08908 | 4/20 | 0.43 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.41 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27016299 | 0.89 | HDAC4 (0.46) | HTR2CHTR2AHDAC4HDAC8 | |
| SCHEMBL6709239 | 0.84 | HTR6 (0.44) | HTR2CHTR6SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL25085649 | 0.83 | HTR6 (0.43) | HTR2CHTR6SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL25691218 | 0.81 | ALDH1A1 (0.48) | HTR2CHTR2AHTR6HDAC4HDAC8 | |
| SCHEMBL20458024 | 0.80 | HTR2C (0.54) | HTR2CHTR6SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL22542016 | 0.80 | SLC6A2 (0.63) | HTR2CHTR2AHTR6SLC6A2SLC6A4 | |
| SCHEMBL2707057 | 0.80 | HTR2C (0.63) | HTR2CHTR2AHTR6SLC6A2SLC6A4 | |
| SCHEMBL15785387 | 0.78 | HTR6 (0.45) | HTR2CHTR6SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL5669793 | 0.78 | HTR2C (0.61) | HTR2CHTR2AHTR6SLC6A2SLC6A4 | |
| SCHEMBL23712339 | 0.78 | HTR2C (0.61) | HTR2CHTR2ASLC6A2SLC6A4SLC6A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220168313-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | SAGARD HOLDINGS MANAGER LP, AS ADMINISTRATIVE AGENT (CA) | 2022-06-02 | — | — | US | disclosed |
| US-20220162229-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | SAGARD HOLDINGS MANAGER LP, AS ADMINISTRATIVE AGENT (CA) | 2022-05-26 | — | — | US | disclosed |
| US-10807994-B2 | Heterocyclic compounds and uses thereof | NUVATION BIO INC. (US) | 2020-10-20 | — | — | US | disclosed |
| US-20190106436-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | SAGARD HOLDINGS MANAGER LP, AS ADMINISTRATIVE AGENT (CA) | 2019-04-11 | — | — | US | disclosed |
| US-20040147557-A1 | Aryl piperidine derivatives as inducers of ldl-receptor expression | BOUILLOT ANNE (FR) | 2004-07-29 | — | — | US | disclosed |
| US-20040077654-A1 | Aryl piperidine and piperazine derivatives as inducers of ldl-receptor expression | SMITHKLINE BEECHAM CORPORATION | 2004-04-22 | — | — | US | disclosed |
| US-6673555-B1 | USE OF SREBP CLEAVAGE-ACTIVATING PROTEIN (SCAP) TO SCREEN FOR AGENTS HAVING SCAP BINDING CHARACTERISTICS; USE IN COMBATING DISEASES ASSOCIATED WITH ELEVATED BLOOD LIPID LEVELS; SREBP: STEROL REGULATORY ELEMENT BINDING PROTEIN | SMITHKLINE BEECHAM CORPORATION | 2004-01-06 | — | — | US | disclosed |
| US-20030224347-A1 | Pharmaceutical compositions | GRAND-PERRET THIERRY ANDRE REG (FR) | 2003-12-04 | — | — | US | disclosed |
| US-20030224348-A1 | Methods of screening for SCAP antagonists | GRAND-PERRET THIERRY ANDRE REG (FR) | 2003-12-04 | — | — | US | disclosed |
| EP-1351936-A1 | ARYL PIPERIDINE AND PIPERAZINE DERIVATIVES AS INDUCERS OF LDL-RECEPTOR EXPRESSION | GLAXO GROUP LIMITED (GB) | 2003-10-15 | — | — | EP | disclosed |
| EP-1351937-A1 | ARYL PIPERIDINE DERIVATIVES AS INDUCERS OF LDL-RECEPTOR EXPRESSION | GLAXO GROUP LIMITED (GB) | 2003-10-15 | — | — | EP | disclosed |
| WO-2002055497-A1 | ARYL PIPERIDINE DERIVATIVES AS INDUCERS OF LDL-RECEPTOR EXPRESSION | GLAXO GROUP LIMITED (GB) | 2002-07-18 | — | — | WO | disclosed |
| WO-2002055496-A1 | ARYL PIPERIDINE AND PIPERAZINE DERIVATIVES AS INDUCERS OF LDL-RECEPTOR EXPRESSION | GLAXO GROUP LIMITED (GB) | 2002-07-18 | — | — | WO | disclosed |
| EP-1196783-A2 | SCREENING FOR THERAPEUTIC AGENTS BEING SCAP ANTAGONISTS | GLAXO GROUP LIMITED (GB) | 2002-04-17 | — | — | EP | disclosed |
| WO-2001006261-A2 | SCREENING FOR THERAPEUTIC AGENTS BEING SCAP ANTAGONISTS | GLAXO GROUP LIMITED (GB) | 2001-01-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190106436-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | WEE1, WEE2, NME1 | HTR2C 2918/4885HTR2A 4047/4885HTR6 4013/4885 |
| US-20220162229-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | WEE1, WEE2, NME1 | HTR2C 2918/4885HTR2A 4047/4885HTR6 4013/4885 |
| US-20220168313-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | WEE1, WEE2, VHL | HTR2C 3127/4885HTR2A 4191/4885HTR6 3352/4885 |
| US-20040147557-A1 | Aryl piperidine derivatives as inducers of ldl-receptor expression | NR1H2, NR1H3, NR1H4 | HTR2C 233/4885HTR2A 470/4885HTR6 435/4885 |
| US-20040077654-A1 | Aryl piperidine and piperazine derivatives as inducers of ldl-receptor expression | LDLR, NR1H2, NCOR1 | HTR2C 1120/4885HTR2A 526/4885HTR6 705/4885 |
| US-10807994-B2 | Heterocyclic compounds and uses thereof | WEE1, WEE2, CCNE1 | HTR2C 3415/4885HTR2A 4466/4885HTR6 4529/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.